TRIlogy-4

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody

Near Add Your Location

Sorting 16 by

Oregon Health and Science University
OHSU Knight Cancer Institute
Portland, OR
  • Accepting patients
Norton Cancer Institute (St. Matthews)
St. Matthews Campus
Louisville, KY
  • Accepting patients
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
Neag Comprehensive Cancer Center
UConn Health
Farmington, CT
  • Accepting patients
Mission Cancer and Blood
Waukee, IA
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.